[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) - Drugs in Development, 2021

September 2021 | 462 pages | ID: MCAD60746738EN
Global Markets Direct

US$ 2,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus Infections - Drugs In Development, 2021, provides an overview of the Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline landscape.MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 15, 11, 1, 66, 33 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 35 and 25 molecules, respectively.

Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Development
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drug Profiles
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Companies, 2021 (Contd..3)
Number of Products under Development by Companies, 2021 (Contd..4)
Number of Products under Development by Companies, 2021 (Contd..5)
Number of Products under Development by Universities/Institutes, 2021
Number of Products under Development by Universities/Institutes, 2021 (Contd..1)
Number of Products under Development by Universities/Institutes, 2021 (Contd..2)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Products under Development by Companies, 2021 (Contd..7)
Products under Development by Universities/Institutes, 2021
Products under Development by Universities/Institutes, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021 (Contd..2)
Number of Products by Stage and Target, 2021
Number of Products by Stage and Target, 2021 (Contd..1)
Number of Products by Stage and Target, 2021 (Contd..2)
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AbbVie Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Acticule Life Sciences Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AEON Medix Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AimMax Therapeutics Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AlphaMab Co Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Amicrobe Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Amprologix Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AnyGen Co Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corp, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aridis Pharmaceuticals Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Arietis Corp, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aurigene Discovery Technologies Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Basilea Pharmaceutica Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Biomendics LLC, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by BioPlx Microbiomics Pvt Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bioseka UAB, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bioversys AG, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Botanix Pharmaceuticals Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cadila Healthcare Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cantab Anti-infectives Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cellics Therapeutics Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Centivax Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Crestone Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CSA Biotechnologies LLC, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Curza Global LLC, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Daiichi Sankyo Co Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DeNovaMed Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Plc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Eagle Pharmaceuticals Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Enesi Pharma Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ESA Patentverwertungsagentur Sachsen-Anhalt GmbH, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Exbaq LLC, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Galenus Therapeutics Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Biotechnologies Pvt Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Genentech USA Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Global BioLife Inc Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helperby Therapeutics Group Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Hsiri Therapeutics LLC, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by HyPharm GmbH, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ImmunArtes LLC, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Immupharma Plc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Inimmune Corp, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Instituto Biomar SA, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Integrated BioTherapeutics Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ioGenetics Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Johnson & Johnson, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by KBP Biosciences Co Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Kurobe LLC, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lakewood-Amedex Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lead Discovery Center GmbH, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by LegoChem Biosciences Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lysimmune BioScience, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lyticon LLC, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lytix Biopharma AS, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Madam Therapeutics BV, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Matrisys Bioscience Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Meiji Seika Pharma Co Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Melinta Therapeutics Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Merck & Co Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MGB Biopharma Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Microbiotix Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Motif Bio Plc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics Plc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Naicons Srl, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Neupharma Srl, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novabiotics Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovaDigm Therapeutics Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novalex Therapeutics Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Olgram SAS, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Olymvax Biopharmaceuticals Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Opal Biosciences Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Oppilotech Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Oragenics Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Oryn Therapeutics, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Oxford Drug Design Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Peptineo, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Phico Therapeutics Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Procarta Biosystems Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Prommune Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Q2 Pharma Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by QureTech Bio AB, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Recce Pharmaceuticals Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sano Chemicals Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Scandion Oncology AS, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by SciBac Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sentinella Pharmaceuticals Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Shanghai Space Peptides Pharmaceutical Co Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sinsa Labs Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Skye Bioscience Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Soligenix Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sorrento Therapeutics Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Synspira Therapeutics Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TaeJoon Pharmaceuticals Co Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TAXIS Pharmaceuticals Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TGV-Inhalonix Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Theravance Biopharma Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Trellis Bioscience Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Valevia UK Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Venomyx Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Viosera Therapeutics, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Vitas Pharma Research Pvt Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by VLP Biotech Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wockhardt Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by XBiotech Inc, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Yungjin Pharm Co Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, 2021
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, 2021 (Contd..1)
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, 2021 (Contd..2)
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, 2021 (Contd..3)
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, 2021 (Contd..4)
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, 2021 (Contd..5)
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, 2021 (Contd..6)
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, 2021 (Contd..7)
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, 2021 (Contd..8)
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products, 2021

LIST OF FIGURES

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021


More Publications